[go: up one dir, main page]

MA30405B1 - Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3 - Google Patents

Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3

Info

Publication number
MA30405B1
MA30405B1 MA31370A MA31370A MA30405B1 MA 30405 B1 MA30405 B1 MA 30405B1 MA 31370 A MA31370 A MA 31370A MA 31370 A MA31370 A MA 31370A MA 30405 B1 MA30405 B1 MA 30405B1
Authority
MA
Morocco
Prior art keywords
benzylphtalazinone
derivatives
substituted
histamine antagonists
histamine
Prior art date
Application number
MA31370A
Other languages
English (en)
Inventor
Paul Martin Gore
Ashley Paul Hancock
Simon Teanby Hodgson
Leanda Jane Kindon
Panayiotis Alexandrou Procopiou
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0607839A external-priority patent/GB0607839D0/en
Priority claimed from GB0706160A external-priority patent/GB0706160D0/en
Priority claimed from GB0706176A external-priority patent/GB0706176D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA30405B1 publication Critical patent/MA30405B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (I), et leurs sels, des procédés pour leur préparation, des compositions les contenant et leur utilisation dans le traitement de diverses pathologies, telles que la rhinite allergique.
MA31370A 2006-04-20 2008-11-10 Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3 MA30405B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0607839A GB0607839D0 (en) 2006-04-20 2006-04-20 Compounds
GB0706160A GB0706160D0 (en) 2007-03-29 2007-03-29 Compounds
GB0706176A GB0706176D0 (en) 2007-03-29 2007-03-29 Compounds

Publications (1)

Publication Number Publication Date
MA30405B1 true MA30405B1 (fr) 2009-05-04

Family

ID=38226516

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31370A MA30405B1 (fr) 2006-04-20 2008-11-10 Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3

Country Status (19)

Country Link
US (2) US20080039444A1 (fr)
EP (1) EP2007735B1 (fr)
JP (1) JP4489143B2 (fr)
KR (1) KR20090007604A (fr)
AR (1) AR060535A1 (fr)
AT (1) ATE486063T1 (fr)
AU (1) AU2007242842A1 (fr)
BR (1) BRPI0710156A2 (fr)
CA (1) CA2649029A1 (fr)
CO (1) CO6140030A2 (fr)
CR (1) CR10356A (fr)
DE (1) DE602007010118D1 (fr)
EA (1) EA200801996A1 (fr)
MA (1) MA30405B1 (fr)
MX (1) MX2008013406A (fr)
NO (1) NO20084363L (fr)
PE (1) PE20080360A1 (fr)
TW (1) TW200811116A (fr)
WO (1) WO2007122156A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
ATE459358T1 (de) * 2006-12-20 2010-03-15 Glaxo Group Ltd 4-benzyl-1(2h)-phthalazinone als h1-rezeptor- antagonisten
CL2008003036A1 (es) * 2007-10-16 2009-05-08 Glaxo Group Ltd Composicion farmaceutica acuosa que comprende 4-[(4-clorofenil)metil]-2-({(2r)-1-[4-(4-{[3-(hexahidro-1h-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2h)-ftalazinona; envase que la comprende; y uso para el tratamiento de enfermedades inflamatorias y/o alergicas tal como rinitis alergica.
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
GB0811447D0 (en) * 2008-06-20 2008-07-30 Glaxo Group Ltd Formulations
WO2010094643A1 (fr) 2009-02-17 2010-08-26 Glaxo Group Limited Dérivés de quinoline et applications associées dans la rhinite et l'urticaire
US20120157446A1 (en) * 2009-06-29 2012-06-21 Glaxo Group Limited Medical use
CA2798007C (fr) 2010-05-19 2018-10-23 Sandoz Ag Preparation d'intermediaires pour la preparation de posaconazole
AU2011254656B2 (en) 2010-05-19 2015-04-16 Sandoz Ag Process for the preparation of chiral hydrazides
BR112012029228A2 (pt) * 2010-05-19 2021-08-03 Sandoz Ag processo para a preparação de um sal de cloreto de hidrogênio, sal de cloreto de hidrogênio, sal de cloreto de hidrogênio cristalino, uso de um sal e uso do processo
WO2012045729A1 (fr) 2010-10-05 2012-04-12 Glaxo Group Limited Dérivés d'imidazo[1,2-a]pyridine et de pyrazolo[1,5-a]pyridine en tant qu'antagonistes du trpv1
WO2012072512A1 (fr) 2010-11-29 2012-06-07 Glaxo Group Limited Carboxamides de n-cyclo-butylimidazopyridine ou de n-cyclo-pyrazolopyridine comme antagonistes de trpv1
US8754101B2 (en) 2011-04-11 2014-06-17 Glaxo Group Limited N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists
CN108329303A (zh) 2011-06-16 2018-07-27 桑多斯股份公司 制备手性化合物的方法
WO2013151982A1 (fr) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés
MX2016014859A (es) 2014-05-12 2017-06-27 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
BR112022019245A2 (pt) 2020-03-26 2022-11-16 Glaxosmithkline Ip Dev Ltd Inibidores de catepsina para prevenir ou tratar infecções virais
WO2022251497A1 (fr) * 2021-05-27 2022-12-01 Schrödinger, Inc. Composés hétérocycliques et procédés d'utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH572914A5 (fr) * 1971-01-22 1976-02-27 Asta Werke Ag Chem Fab
US3813384A (en) * 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
ATE49205T1 (de) * 1984-09-14 1990-01-15 Asta Pharma Ag Substituierte benzylphthalazinon-derivate.
ES2031813T3 (es) * 1985-11-11 1993-01-01 Asta Pharma Ag Procedimiento para la preparacion de derivados de 4-bencil-1-(2h)-ftalazinona.
EP0289939A1 (fr) * 1987-05-08 1988-11-09 ASTA Pharma AG Dérivés du 4-benzyl-1-(2H)-phtalazinone avec un radical acide aminé
CZ199593A3 (en) * 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
US6180629B1 (en) * 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
ES2209337T3 (es) * 1998-08-14 2004-06-16 Pfizer Inc. Agentes antitromboticos.
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
AU2004222336B2 (en) * 2003-03-18 2010-06-03 Merck Sharp & Dohme Corp. Amino cyclobutylamide modulators of chemokine receptor activity
JP4735261B2 (ja) * 2003-06-27 2011-07-27 Ｍｓｄ株式会社 ヘテロアリールオキシ含窒素飽和ヘテロ環誘導体

Also Published As

Publication number Publication date
BRPI0710156A2 (pt) 2012-06-05
US20090105225A1 (en) 2009-04-23
ATE486063T1 (de) 2010-11-15
AR060535A1 (es) 2008-06-25
WO2007122156A9 (fr) 2008-01-24
CO6140030A2 (es) 2010-03-19
JP4489143B2 (ja) 2010-06-23
KR20090007604A (ko) 2009-01-19
PE20080360A1 (es) 2008-05-22
WO2007122156A1 (fr) 2007-11-01
MX2008013406A (es) 2008-11-04
CA2649029A1 (fr) 2007-11-01
EP2007735A1 (fr) 2008-12-31
DE602007010118D1 (de) 2010-12-09
EP2007735B1 (fr) 2010-10-27
EA200801996A1 (ru) 2009-04-28
TW200811116A (en) 2008-03-01
US20080039444A1 (en) 2008-02-14
NO20084363L (no) 2008-11-17
AU2007242842A1 (en) 2007-11-01
CR10356A (es) 2008-11-26
JP2009534351A (ja) 2009-09-24

Similar Documents

Publication Publication Date Title
MA30405B1 (fr) Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3
TN2011000316A1 (fr) Derives de sulfonamides
TN2009000450A1 (fr) Derives de pyridine
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
TNSN07022A1 (fr) Derives de pyridine
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA29926B1 (fr) Derives de pyrazine
MA29535B1 (fr) Derives d'isoquinoline utilises en tant qu'inhibiteurs de rhokinase
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA31894B1 (fr) Composes organiques
MA32134B1 (fr) Composés hétérocycliques
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA31766B1 (fr) Composés organiques
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
MA30221B1 (fr) Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments
MA31021B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees en tant qu'inhibiteurs de la rho-kinase
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA31903B1 (fr) Derives de thiazole utilises comme inhibiteur de la pi 3 kinase
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer